0.11% +0.0476

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스

Closing Bell Recap: Soleno Therapeutics Inc (SLNO) Ends at 45.21, Reflecting a 3.93 Upturn – DWinneX - The Dwinnex

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community - GlobeNewswire

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community

Soleno Therapeutics (NASDAQ:SLNO) Upgraded to Strong-Buy by Baird R W - MarketBeat

Painful week for private equity firms invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) after 8.5% drop, institutions also suffered losses - Simply Wall St

Robert W. Baird Initiates Coverage on Soleno Therapeutics (NASDAQ:SLNO) - Defense World

Learn to Evaluate (SLNO) using the Charts - Stock Traders Daily

Oppenheimer Cuts Soleno Therapeutics (NASDAQ:SLNO) Price Target to $59.00 - MarketBeat

Oppenheimer cuts Soleno Therapeutics stock target By Investing.com - Investing.com Canada

Oppenheimer cuts Soleno Therapeutics stock target By Investing.com - Investing.com UK

Oppenheimer cuts Soleno Therapeutics stock target - Investing.com ZA - Investing.com South Africa

Soleno Therapeutics (NASDAQ:SLNO) Shares Down 6.1% - Defense World

Soleno Therapeutics (NASDAQ:SLNO) Trading Down 6.1% - MarketBeat

Baird sets stock target on Soleno Therapeutics shares - Investing.com Australia

Soleno Therapeutics (NASDAQ:SLNO) Now Covered by Robert W. Baird - MarketBeat

Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Price Target at $55.60 - MarketBeat

Solerno a new outperform at Baird on lead candidate for Prader-Willi syndrome - Seeking Alpha

Baird sets stock target on Soleno Therapeutics shares - Investing.com South Africa

Soleno Therapeutics' $130 Million Common Stock Offering – Global Legal Chronicle - Global Legal Chronicle

Baird sets stock target on Soleno Therapeutics shares - Investing.com

Baird sets stock target on Soleno Therapeutics shares - Investing.com Canada

Baird sets stock target on Soleno Therapeutics shares - Investing.com UK

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - Yahoo Finance

Vivo Capital LLC Has $338.83 Million Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat

Have Insiders Been Buying Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares? - Yahoo Movies UK

Prader-willi Syndrome Market to Exhibit Moderate Growth Rate During the Forecast Period - openPR

Wilson Sonsini Advises Soleno Therapeutics on $138 Million Public Offering - Wilson Sonsini

Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Down to $49.23 - MarketBeat

Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock - GlobeNewswire

Soleno Therapeutics plans stock offering to fund research - Investing.com

Soleno Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

Vivo opportunity fund holdings sells over $51 million in Soleno Therapeutics stock - Investing.com

Technical analysis of Soleno Therapeutics Inc (SLNO) stock chart patterns – US Post News - US Post News

Vivo opportunity fund holdings sells over $51 million in Soleno Therapeutics stock - Investing.com India

Potential Price Increase for Soleno Therapeutics Inc (SLNO) After Recent Insider Activity – Knox Daily - Knox Daily

Soleno reports promising results for Prader-Willi syndrome treatment - Investing.com India

US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?

Why Soleno Therapeutics Stock Is Skyrocketing Today

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

FDA grants breakthrough status to Soleno's PWS drug By Investing.com - Investing.com

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Trade Alert: President Of Soleno Therapeutics Anish Bhatnagar Has Sold Stock - Simply Wall St

CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO) - Yahoo Finance

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn - Simply Wall St

Soleno Therapeutics Corrects Q4 Financial Reporting Error - TipRanks.com - TipRanks

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results - Yahoo Finance

SLNO과 유사한 종목